CPT 0531U: NeXGen™ Fungal/AFB NGS Assay, Plasma-Based Pathogen ID

CPT code 0531U designates the NeXGen™ Fungal/AFB NGS Assay from Eurofins Viracor LLC, a Proprietary Laboratory Analyses (PLA) test that uses next-generation sequencing on plasma to detect and identify DNA from 673 acid–fast bacteria and invasive fungi. As a PLA code, 0531U is specific to a single manufacturer's assay and is used to report advanced molecular pathogen identification that can influence infectious disease diagnosis and management. Nationally, PLA codes like 0531U matter because they track use of proprietary diagnostics, inform coverage and payment policies, and reflect the adoption of broad-range NGS methods in clinical care.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose and service setting for this assay, national payer coverage context, and the types of benchmarking and policy considerations typically associated with proprietary NGS diagnostics. The publication presents expected benchmarks around utilization and reimbursement structures for PLA tests, highlights policy implications for payer coverage and prior authorization practices, and summarizes clinical context where broad-range fungal and acid-fast bacterial identification from plasma is relevant.

Data not available in the input for specific payer coverage determinations, associated taxonomies, ICD-10 diagnoses, related codes, and service line details.

Billing Code Overview

CPT code 0531U is a Proprietary Laboratory Analyses (PLA) code for the NeXGen™ Fungal/AFB NGS Assay produced by Eurofins Viracor LLC. The test detects and identifies DNA from 673 acid–fast bacteria and invasive fungi using next-generation sequencing (NGS) technology. It is reported only for this specific laboratory's assay.

Service Type: Clinical laboratory test — plasma-based next-generation sequencing for infectious disease detection.

Typical Site of Service: Clinical laboratory processing using plasma samples; specimen collection generally occurs in outpatient clinics, hospital outpatient departments, or ambulatory collection centers.

Clinical Context

A 58-year-old immunocompromised patient with persistent fever, cough, and radiographic pulmonary nodules is admitted to the hospital after broad-spectrum antibacterial therapy fails to resolve symptoms. Blood cultures are negative. The infectious disease team orders the NeXGen™ Fungal/AFB NGS Assay to detect circulating cell-free DNA from invasive fungi and acid–fast bacteria to guide targeted antimicrobial therapy. Plasma is collected in an outpatient clinic or inpatient phlebotomy lab and shipped to Eurofins Viracor LLC. Results typically return within several days; the laboratory report identifies species-level pathogens or reports no pathogen detected. The test supports diagnosis when tissue biopsy is high-risk or prior testing (cultures, antigen/serology, PCR panels) is non-diagnostic, and it informs escalation, narrowing, or discontinuation of antifungal or antimycobacterial treatment.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when documentation supports substantially greater physician work, such as extensive coordination for complex specimen acquisition or interpretive effort beyond the typical report.
`52`	Reduced services

Taxonomy Code	Specialty	Notes
207RX0400X	Infectious Disease	ID clinicians commonly order and interpret NGS infectious disease assays.
207K00000X	Pulmonary Disease	Pulmonologists manage patients with suspected invasive fungal or mycobacterial lung infections and order testing.
207Q00000X	Critical Care Medicine	Critical care physicians order testing for seriously ill, immunocompromised patients in ICU.
261QP2300X	Clinical Pathology	Laboratory directors and clinical pathologists oversee testing validity and result interpretation.
207L00000X	Allergy & Immunology	Specialists managing immunodeficiency may order advanced pathogen testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`B37.9`	Candidiasis, unspecified	Invasive candidiasis can cause persistent fungemia or deep-seated infection; NGS may detect circulating fungal DNA.
`B38.4`	Coccidioidomycosis, disseminated	Disseminated fungal infections are targets for broad NGS pathogen detection when conventional tests are inconclusive.
`B44.9`	Aspergillosis, unspecified	Invasive aspergillosis is a common concern in immunocompromised patients and may be identified by plasma NGS.
`A31.9`	Mycobacteriosis, unspecified	Non-tuberculous mycobacterial infections can be difficult to culture; NGS can detect acid–fast bacterial DNA.
`A15.0`	Tuberculosis of lung	Pulmonary tuberculosis is an acid–fast bacterial infection that may be detected when other tests are non-diagnostic.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0531U`	NeXGen™ Fungal/AFB NGS Assay — detects and identifies DNA from 673 acid–fast bacteria and invasive fungi using NGS on plasma	Primary code for the proprietary plasma NGS assay performed by Eurofins Viracor LLC.
`0002U`	Metagenomic sequencing, pathogen detection, unspecified specimen (example PLA code)	Other PLA NGS assays may be performed in parallel or as alternatives depending on laboratory availability.
`87481`	Infectious agent detection by nucleic acid (e.g., PCR), each organism	Targeted molecular tests for specific fungi or mycobacteria may be ordered before or after NGS for confirmation.
`86328`	Antibody; infectious agent specific (qualitative, single step method)	Serologic tests to support diagnosis of some fungal infections may be ordered alongside NGS.
`87070`	Culture, bacterial, any source, other than blood, with isolation and presumptive identification of isolates	Conventional microbiology cultures may be performed in parallel when specimen types permit to obtain isolates for susceptibility testing.

OpenPayer

Summary & Overview